Quarterly report pursuant to Section 13 or 15(d)

INSTALLMENT PAYMENTS - LICENSES

v3.22.1
INSTALLMENT PAYMENTS - LICENSES
3 Months Ended
Mar. 31, 2022
INSTALLMENT PAYMENTS - LICENSES  
INSTALLMENT PAYMENTS - LICENSES

NOTE 11. INSTALLMENT PAYMENTS — LICENSES

The following tables show the details of the Company’s installment payments – licenses for the periods presented:

    

March 31, 2022

    

    

    

($'s in thousands)

    

Ximino (1)

    

Accutane (2)

    

Total

Installment payments - licenses, short-term

$

2,000

$

1,000

$

3,000

Less: imputed interest

 

(379)

 

(52)

 

(431)

Sub-total installment payments - licenses, short-term

1,621

948

2,569

Installment payments - licenses, long-term

3,000

1,000

4,000

Less: imputed interest

(271)

(13)

(284)

Sub-total installment payments - licenses, long-term

2,729

987

3,716

Total installment payments - licenses

$

4,350

$

1,935

$

6,285

    

December 31, 2021

    

    

    

Anti-Itch

    

($'s in thousands)

    

Ximino (1)

    

Accutane (2)

    

Product (3)

    

Total

Installment payments - licenses, short-term

$

2,000

$

2,000

$

1,000

$

5,000

Less: imputed interest

 

(425)

 

(65)

 

-

 

(490)

Sub-total installment payments - licenses, short-term

1,575

1,935

1,000

4,510

Installment payments - licenses, long-term

3,000

1,000

4,000

Less: imputed interest

 

(350)

 

(23)

 

 

(373)

Sub-total installment payments - licenses, long-term

2,650

977

3,627

Total installment payments - licenses

$

4,225

$

2,912

$

1,000

$

8,137

Note 1: Imputed interest rate of 11.96% and maturity date of July 22, 2024.

Note 2: Imputed interest rate of 4.03% and maturity date of July 29, 2023.

Note 3: Imputed interest rate of 4.25% and maturity date of January 1, 2022.